According to the sources provided, there is limited information specifically addressing whether the dosage of Yervoy (ipilimumab) should be adjusted for overweight patients. However, we can gather some insights from the available information.

Yervoy is an immunotherapy drug used for the treatment of various cancers, including melanoma. It works by activating the immune system to target and destroy cancer cells [1]. The recommended dosage of Yervoy for melanoma is 3 mg/kg every 3 weeks for a total of four doses [1].

When it comes to adjusting the dosage of Yervoy for overweight patients, the available sources do not provide explicit guidance. However, it is important to note that the dosage of Yervoy is weight-based, with the recommended dose being 3 mg/kg [1]. This suggests that the dosage is already adjusted based on the patient's weight.

It is worth mentioning that the sources provided do not specifically discuss the impact of weight on the efficacy or safety of Yervoy. However, the sources do provide general information about the drug's mechanism of action, dosing guidelines, and potential side effects.

In conclusion, based on the available information, there is no explicit guidance on adjusting the dosage of Yervoy for overweight patients. However, since the recommended dosage is weight-based, it can be inferred that the dosage already takes into account the patient's weight. It is important for healthcare professionals to consider individual patient factors, including weight, when determining the appropriate dosage of Yervoy.

Sources:
[1] Drug Patent Watch. (n.d.). Yervoy. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] National Center for Biotechnology Information. (2021). Ipilimumab. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134762/
[3] Pubmed. (2019). Ipilimumab (Yervoy) in the treatment of melanoma: the importance of early recognition and management of immune-related adverse events. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30922394/